For osteoporosis, many studies have suggested that long-term treatment with RPD increases the risk of osteoporosis by elevating serum prolactin levels (De Hert et al., 2016; Zheng et al., 2019; Chen Y. et al., 2021). The gene discussed is PRL; the disease is osteoporosis.